Oncology Clinical Trials in India: Expanding Opportunities for Early- and Late-Phase Research
INTRODUCTION India is rapidly establishing itself as a global destination for oncology clinical trials. With a population of 1.4 billion, a growing cancer burden, diverse patient populations, experienced investigators, and evolving regulatory frameworks, the country offers substantial opportunities for both early-phase and late-phase oncology studies. Over the last two decades, India has transformed by developing […]
Navigating the Regulatory Landscape for Clinical Trials in India
Introduction: Understanding Clinical Trial Regulations in India When the CLINEXEL team attends international conferences, we receive a lot of queries from Clinical Trial Leaders, particularly from emerging biotech companies, regarding the clinical trial environment in India, regulatory timelines, approval processes, operational challenges, and key strategic considerations. This article provides an overview of the evolving regulatory […]
Role of India in Rescue Trials for Accelerating Clinical Development When Timelines Are at Risk: A Perspective by CLINEXEL-AICROS
Introduction: When Clinical Trials Need a Course Correction Clinical trials rarely proceed exactly as planned. Despite rigorous feasibility assessments, protocol optimization, and careful site selection, studies can still face unexpected delays. Slow patient recruitment, high screen failure rates, operational inefficiencies, or increased competition from parallel trials can derail timelines. In such situations, sponsors often initiate […]
India’s Strategic Role in Multi-Regional Clinical Trials (MRCTs): A Balanced Approach to Global Clinical Development
Introduction to India’s Role in Multi-Regional Clinical Trials (MRCTs) and Global Clinical Development As multi-regional clinical trials (MRCTs) continue to shape modern drug development, sponsors must design studies that are globally relevant, operationally efficient, and regulatorily robust. In this evolving landscape, India has emerged as a key contributor in global clinical trials and MRCT strategies. […]
CLINEXEL – AICROS: How to Select Countries for a Multi-Regional Clinical Trial (MRCT): A Strategic Guide
Introduction: The global clinical development landscape is undergoing a period of recalibration. Rising trial costs, constrained funding environments, and persistent macroeconomic pressures such as inflation are forcing sponsors to rethink how and where they conduct studies. These pressures are not abstract; they translate directly into slower development timelines, delayed decision-making, and increased risk for sponsors. […]
Database Lock in Clinical Trials: Top Data Management Mistakes & Clinexel Solutions
What is Database Lock in Clinical Trials and Why It Matters In clinical trials, Database lock in clinical trials is the final and most critical step in the clinical data lifecycle, where all collected data is cleaned, verified, reconciled, and finalized before statistical analysis and regulatory submission. Delays in the clinical trial database lock process […]
Why Include India in Global Clinical Trials: Benefits, Regulations & CRO Insights.
Pharma companies planning to conduct global clinical trials in India often have questions about the approval process and regulatory requirements. In addition, many sponsors seek to understand the advantages of including India in global clinical trials, such as access to a large and diverse patient population, experienced investigators, and cost efficiencies. Before outsourcing clinical trials […]
Clinical Trial Regulatory Framework in India: Complete Guide (NDCTR & CDSCO)
Introduction Companies planning to conduct clinical trials in India often have queries regarding the clinical trial approval process in India and the overall regulatory pathway. Before outsourcing clinical trials to Contract Research Organizations in India, it is essential to understand the clinical trial regulatory framework in India and how different regulatory components interact. India has […]
Antimicrobial Clinical Trials in India: Opportunities, Scientific Strengths, and the Way Forward
Introduction Antimicrobial clinical trials in India are becoming increasingly critical in the global fight against antimicrobial resistance (AMR). With rising resistance rates and a high infectious disease burden, India presents a unique opportunity to accelerate antimicrobial resistance clinical research while generating globally relevant data. Globally, nearly 30% of bacterial infections show resistance to commonly used […]
CDSCO New Drugs and Clinical Trials (Amendment) Rules, 2026: A Major Step Towards Streamlining Clinical Research in India
Introduction In January 2026, The Ministry of Health and Family Welfare of India notified the New Drugs and Clinical Trials (Amendment) Rules, 2026, introducing important refinements to the New Drugs and Clinical Trials (NDCT) Rules, 2019. These amendments reflect India’s continued commitment to strengthening its clinical research ecosystem while improving regulatory efficiency. As a full-service […]